ArticleProceedings of the National Academy of Sciences of the United States of America2025
Design and structural basis of selective 1,4-dihydropyridine inhibitors of the calcium-activated potassium channel K
Seow Theng Ong, Young-Woo Nam, Joshua A Nasburg, Alena Ramanishka, Xuan Rui Ng, Zhong Zhuang, Stephanie Shee Min Goay, Hai M Nguyen, Latika Singh, Vikrant Singh and 7 more
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Seow Theng OngLee Kong Chian School of Medicine-Innovative CRO Explorer Collaborative Platform, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921, Singapore.ORCID 0000-0001-6089-4745
Young-Woo NamDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618.
Joshua A NasburgDepartment of Pharmacology, School of Medicine, University of California, Davis, CA 95616.
Alena RamanishkaDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618.
Xuan Rui NgLee Kong Chian School of Medicine-Innovative CRO Explorer Collaborative Platform, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921, Singapore.ORCID 0009-0006-6389-252X
Zhong ZhuangLee Kong Chian School of Medicine-Innovative CRO Explorer Collaborative Platform, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921, Singapore.
Stephanie Shee Min GoayLee Kong Chian School of Medicine-Innovative CRO Explorer Collaborative Platform, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921, Singapore.
Hai M NguyenDepartment of Pharmacology, School of Medicine, University of California, Davis, CA 95616.ORCID 0000-0002-1422-7041
Latika SinghDepartment of Pharmacology, School of Medicine, University of California, Davis, CA 95616.
Vikrant SinghDepartment of Pharmacology, School of Medicine, University of California, Davis, CA 95616.
Alicia RiveraDivision of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA 02215.ORCID 0000-0002-0433-6367
M Elaine EysterDivision of Blood and Vascular Disorders, Department of Medicine, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, PA 17033.ORCID 0000-0001-8248-6793
Yang XuDivision of Cryogenic Electron Microscopy and Bioimaging, Stanford Synchrotron Radiation Lightsource, Stanford Linear Accelerator Center National Accelerator Laboratory, Stanford University, Menlo Park, CA 94025.
Seth L AlperDivision of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA 02215.ORCID 0000-0002-6228-2512
Heike WulffDepartment of Pharmacology, School of Medicine, University of California, Davis, CA 95616.ORCID 0000-0003-4437-5763
Miao ZhangDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618.ORCID 0000-0002-3099-155X
K George ChandyLee Kong Chian School of Medicine-Innovative CRO Explorer Collaborative Platform, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921, Singapore.ORCID 0000-0002-0557-6143
Funding
Training and Education CoreU54NS079202 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEIN, PAMELA J · 2012 to 2021
$35.7M
The Stanford-SLAC CryoEM CenterR24GM154186 · NIGMS · STANFORD UNIVERSITY · PI Wah Chiu, BRITT HEDMAN · 2024 to 2026
$19.3M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
Development of SK channel modulators as therapeutic agents for ataxiaR33NS101182 · NINDS · CHAPMAN UNIVERSITY · PI BEZPROZVANNY, ILYA B, ZHANG, MIAO · 2021 to 2021
$723k
Channelopathy of KCa2.3 and Zimmermann-Laband syndromeR15NS130420 · NINDS · CHAPMAN UNIVERSITY · PI ZHANG, MIAO · 2024 to 2024
$434k
American Heart Association (AHA) 23AIREA1039423American Heart Association (AHA) 24CDA1260237CounterACT program U54NS079202HHS | National Institutes of Health (NIH) 1R15NS130420-01A1HHS | National Institutes of Health (NIH) 4R33NS101182-03Ministry of Health -Singapore (MOH) CIRG1427-2015National Institute of General Medical Sciences funded Pharmacology Training Program T32GM099608National Institutes of General Medical Sciences 1R24GM154186NIGMS NIH HHS R24 GM154186NIGMS NIH HHS T32 GM099608NINDS NIH HHS R15 NS130420NINDS NIH HHS R33 NS101182NINDS NIH HHS U54 NS079202NTU | Lee Kong Chian School of Medicine, Nanyang Technological University (LKCMedicine) Startup Fund
6 · The paper itself
Abstract
The 1,4-dihydropyridines, drugs with well-established bioavailability and toxicity profiles, have proven efficacy in treating human hypertension, peripheral vascular disorders, and coronary artery disease. Every 1,4-dihydropyridine in clinical use blocks L-type voltage-gated calcium channels. We now report our development, using selective optimization of a side activity (SOSA), of a class of 1,4-dihydropyridines that selectively and potently inhibit the intermediate-conductance calcium-activated K
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Design and structural basis of selective 1,4-dihydropyridine inhibitors of the calcium-activated potassium channel K · full record | OpenQuestion